For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Cancer involves the spontaneous emergence of cells that lose their ability regulate their cell growth and proliferation. However, the biology of cancer is much more complex than just the presence of tumor cells, involving a tumor microenvironment comprised of neovasculature, stromal cells, and inflammatory cells, as well as regions of hypoxia, necrosis, and vascular leak. Our fluorescent imaging probes provide a variety of tools for quantifying key receptors or proteins associated with tumor burden, metabolism, inflammation, protease activity and vascular leak.
The availability of probes at 680 nm and 750 nm wavelengths further offer the opportunity for multiplex imaging of appropriate probe combinations to maximize information gained from research animals.
The Oncology In Vivo Fluorescent Agents Panel includes the following five probes:
|Part Number||Fluorescent Probe||Biological Target|
|NEV10001EX||ProSense 750 EX||Pan-cathepsin activatable probe:
Lysosomal marker of a variety of inflammatory cells
|NEV10040||FolateRSense 680||Folate receptor targeted probe:
Marker on inflammatory cells; metabolic marker on tumor cells
|NEV10054EX||AngioSense 680 EX||Vascular probe:
Leaks into sites of neovascular formation
|NEV10168||MMPSense 750 FAST||Pan-MMP activatable probe:
Secreted protease from inflammatory cells and tumor cells
|NEV10873||IntegriSense 750||αVβ3 integrin targeted probe:
Marker on activated tumors and neovasculature
|Optical Imaging Classification||Fluorescence Imaging|
|Quantity in a Package Amount||5.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||1 vial|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
User guide for fluorescent imaging probes
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.